TY - JOUR
T1 - Behçet syndrome
AU - Yazici, Yusuf
AU - Hatemi, Gulen
AU - Bodaghi, Bahram
AU - Cheon, Jae Hee
AU - Suzuki, Noburu
AU - Ambrose, Nicola
AU - Yazici, Hasan
N1 - Publisher Copyright:
© 2021, Springer Nature Limited.
PY - 2021/12
Y1 - 2021/12
N2 - Behçet syndrome is a systemic vasculitis with an unknown aetiology affecting the small and large vessels of the venous and arterial systems. The presence of symptom clusters, regional differences in disease expression and similarities with, for example, Crohn’s disease suggest that multiple pathological pathways are involved in Behçet syndrome. These disease features also make formulating disease criteria difficult. Genetic studies have identified HLA-B*51 as a genetic risk factor. However, the low prevalence of HLA-B*51 in many patients with bona fide disease, especially in non-endemic regions, suggests that other factors must also be operative in Behçet syndrome. Despite lacking a clear aetiological mechanism and definition, management of manifestations that include major vascular disease, eye disease and central nervous system involvement has improved with the help of new technology. Furthermore, even with our incomplete understanding of disease mechanisms, the prognoses of patients with Behçet syndrome, including those with eye disease, continue to improve. New treatment options and a better understanding of the underlying pathogenesis for various manifestations of this condition are required to further improve the management of the disease, which will improve patient quality of life.
AB - Behçet syndrome is a systemic vasculitis with an unknown aetiology affecting the small and large vessels of the venous and arterial systems. The presence of symptom clusters, regional differences in disease expression and similarities with, for example, Crohn’s disease suggest that multiple pathological pathways are involved in Behçet syndrome. These disease features also make formulating disease criteria difficult. Genetic studies have identified HLA-B*51 as a genetic risk factor. However, the low prevalence of HLA-B*51 in many patients with bona fide disease, especially in non-endemic regions, suggests that other factors must also be operative in Behçet syndrome. Despite lacking a clear aetiological mechanism and definition, management of manifestations that include major vascular disease, eye disease and central nervous system involvement has improved with the help of new technology. Furthermore, even with our incomplete understanding of disease mechanisms, the prognoses of patients with Behçet syndrome, including those with eye disease, continue to improve. New treatment options and a better understanding of the underlying pathogenesis for various manifestations of this condition are required to further improve the management of the disease, which will improve patient quality of life.
UR - http://www.scopus.com/inward/record.url?scp=85115321103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115321103&partnerID=8YFLogxK
U2 - 10.1038/s41572-021-00301-1
DO - 10.1038/s41572-021-00301-1
M3 - Comment/debate
C2 - 34531393
AN - SCOPUS:85115321103
SN - 2056-676X
VL - 7
JO - Nature Reviews Disease Primers
JF - Nature Reviews Disease Primers
IS - 1
M1 - 67
ER -